Search

Your search keyword '"Kiemeney, L. A."' showing total 148 results
Start Over Author "Kiemeney, L. A." Search Limiters Peer Reviewed
148 results on '"Kiemeney, L. A."'

4. Occult lymph node metastases in patients without residual muscle-invasive bladder cancer at radical cystectomy with or without neoadjuvant chemotherapy: a nationwide study of 5417 patients

Author

van Hoogstraten, L. M. C., van Gennep, E. J., Kiemeney, L. A. L. M., Witjes, J. A., Voskuilen, C. S., Deelen, M., Mertens, L. S., Meijer, R. P., Boormans, J. L., Robbrecht, D. G. J., Beerepoot, L. V., Verhoeven, R. H. A., Ripping, T. M., van Rhijn, B. W. G., Aben, K. K. H., and Hermans, T. J. N.

Published
2022
Full Text
View/download PDF

6. A Potential Role for the STXBP5-AS1 Gene in Adult ADHD Symptoms

Author

Arias-Vásquez, A., Groffen, A. J., Spijker, S., Ouwens, K. G., Klein, M., Vojinovic, D., Galesloot, T. E., Bralten, J., Hottenga, J. J., van der Most, P. J., Kattenberg, V. M., Pool, R., Nolte, I. M., Penninx, B. W. J. H., Fedko, I. O., Dolan, C. V., Nivard, M. G., den Braber, A., van Duijn, C. M., Hoekstra, P. J., Buitelaar, J. K., Kiemeney, L. A., Hoogman, M., Middeldorp, C. M., Draisma, H. H. M., Vermeulen, S. H., Sánchez-Mora, C., Ramos-Quiroga, J. A., Ribasés, M., The EAGLE-ADHD Consortium, Hartman, C. A., Kooij, J. J. S., Amin, N., Smit, A. B., Franke, B., and Boomsma, D. I.

Published
2019
Full Text
View/download PDF

7. GLRB allelic variation associated with agoraphobic cognitions, increased startle response and fear network activation: a potential neurogenetic pathway to panic disorder

Author

Deckert, J, Weber, H, Villmann, C, Lonsdorf, T B, Richter, J, Andreatta, M, Arias-Vasquez, A, Hommers, L, Kent, L, Schartner, C, Cichon, S, Wolf, C, Schaefer, N, von Collenberg, C R, Wachter, B, Blum, R, Schümann, D, Scharfenort, R, Schumacher, J, Forstner, A J, Baumann, C, Schiele, M A, Notzon, S, Zwanzger, P, Janzing, J G E, Galesloot, T, Kiemeney, L A, Gajewska, A, Glotzbach-Schoon, E, Mühlberger, A, Alpers, G, Fydrich, T, Fehm, L, Gerlach, A L, Kircher, T, Lang, T, Ströhle, A, Arolt, V, Wittchen, H-U, Kalisch, R, Büchel, C, Hamm, A, Nöthen, M M, Romanos, M, Domschke, K, Pauli, P, and Reif, A

Published
2017
Full Text
View/download PDF

9. A rare missense mutation in CHRNA4 associates with smoking behavior and its consequences

Author

Thorgeirsson, T E, Steinberg, S, Reginsson, G W, Bjornsdottir, G, Rafnar, T, Jonsdottir, I, Helgadottir, A, Gretarsdottir, S, Helgadottir, H, Jonsson, S, Matthiasson, S E, Gislason, T, Tyrfingsson, T, Gudbjartsson, T, Isaksson, H J, Hardardottir, H, Sigvaldason, A, Kiemeney, L A, Haugen, A, Zienolddiny, S, Wolf, H J, Franklin, W A, Panadero, A, Mayordomo, J I, Hall, I P, Rönmark, E, Lundbäck, B, Dirksen, A, Ashraf, H, Pedersen, J H, Masson, G, Sulem, P, Thorsteinsdottir, U, Gudbjartsson, D F, and Stefansson, K

Published
2016
Full Text
View/download PDF

11. Fruits and vegetables consumption and the risk of histological subtypes of lung cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC)

Author

Büchner, F. L., Bueno-de-Mesquita, H. B., Linseisen, J., Boshuizen, H. C., Kiemeney, L. A. L. M., Ros, M. M., Overvad, K., Hansen, L., Tjonneland, A., Raaschou-Nielsen, O., Clavel-Chapelon, F., Boutron-Ruault, M.-C., Touillaud, M., Kaaks, R., Rohrmann, S., Boeing, H., Nöthlings, U., Trichopoulou, A., Zylis, D., Dilis, V., Palli, D., Sieri, S., Vineis, P., Tumino, R., Panico, S., Peeters, P. H. M., van Gils, C. H., Lund, E., Gram, I. T., Braaten, T., Martinez, C., Agudo, A., Arriola, L., Ardanaz, E., Navarro, C., Rodríguez, L., Manjer, J., Wirfält, E., Hallmans, G., Rasmuson, T., Key, T. J., Roddam, A. W., Bingham, S., Khaw, K.-T., Slimani, N., Bofetta, P., Byrnes, G., Norat, T., Michaud, D., and Riboli, E.

Published
2010

13. Common variant at 16p11.2 conferring risk of psychosis

Author

Steinberg, S, de Jong, S, Mattheisen, M, Costas, J, Demontis, D, Jamain, S, Pietiläinen, O P H, Lin, K, Papiol, S, Huttenlocher, J, Sigurdsson, E, Vassos, E, Giegling, I, Breuer, R, Fraser, G, Walker, N, Melle, I, Djurovic, S, Agartz, I, Tuulio-Henriksson, A, Suvisaari, J, Lönnqvist, J, Paunio, T, Olsen, L, Hansen, T, Ingason, A, Pirinen, M, Strengman, E, Hougaard, D M, Ørntoft, T, Didriksen, M, Hollegaard, M V, Nordentoft, M, Abramova, L, Kaleda, V, Arrojo, M, Sanjuán, J, Arango, C, Etain, B, Bellivier, F, Méary, A, Schürhoff, F, Szoke, A, Ribolsi, M, Magni, V, Siracusano, A, Sperling, S, Rossner, M, Christiansen, C, Kiemeney, L A, Franke, B, van den Berg, L H, Veldink, J, Curran, S, Bolton, P, Poot, M, Staal, W, Rehnstrom, K, Kilpinen, H, Freitag, C M, Meyer, J, Magnusson, P, Saemundsen, E, Martsenkovsky, I, Bikshaieva, I, Martsenkovska, I, Vashchenko, O, Raleva, M, Paketchieva, K, Stefanovski, B, Durmishi, N, Pejovic Milovancevic, M, Lecic Tosevski, D, Silagadze, T, Naneishvili, N, Mikeladze, N, Surguladze, S, Vincent, J B, Farmer, A, Mitchell, P B, Wright, A, Schofield, P R, Fullerton, J M, Montgomery, G W, Martin, N G, Rubino, I A, van Winkel, R, Kenis, G, De Hert, M, Réthelyi, J M, Bitter, I, Terenius, L, Jönsson, E G, Bakker, S, van Os, J, Jablensky, A, Leboyer, M, Bramon, E, Powell, J, Murray, R, Corvin, A, Gill, M, Morris, D, O'Neill, F A, Kendler, K, Riley, B, Craddock, N, Owen, M J, O'Donovan, M C, Thorsteinsdottir, U, Kong, A, Ehrenreich, H, Carracedo, A, Golimbet, V, Andreassen, O A, Børglum, A D, Mors, O, Mortensen, P B, Werge, T, Ophoff, R A, Nöthen, M M, Rietschel, M, Cichon, S, Ruggeri, M, Tosato, S, Palotie, A, St Clair, D, Rujescu, D, Collier, D A, Stefansson, H, and Stefansson, K

Published
2014
Full Text
View/download PDF

15. Expanding the range of ZNF804A variants conferring risk of psychosis

Author

Steinberg, S, Mors, O, Børglum, A D, Gustafsson, O, Werge, T, Mortensen, P B, Andreassen, O A, Sigurdsson, E, Thorgeirsson, T E, Böttcher, Y, Olason, P, Ophoff, R A, Cichon, S, Gudjonsdottir, I H, Pietiläinen, O P H, Nyegaard, M, Tuulio-Henriksson, A, Ingason, A, Hansen, T, Athanasiu, L, Suvisaari, J, Lonnqvist, J, Paunio, T, Hartmann, A, Jürgens, G, Nordentoft, M, Hougaard, D, Norgaard-Pedersen, B, Breuer, R, Möller, H-J, Giegling, I, Glenthøj, B, Rasmussen, H B, Mattheisen, M, Bitter, I, Réthelyi, J M, Sigmundsson, T, Fossdal, R, Thorsteinsdottir, U, Ruggeri, M, Tosato, S, Strengman, E, Kiemeney, L A, Melle, I, Djurovic, S, Abramova, L, Kaleda, V, Walshe, M, Bramon, E, Vassos, E, Li, T, Fraser, G, Walker, N, Toulopoulou, T, Yoon, J, Freimer, N B, Cantor, R M, Murray, R, Kong, A, Golimbet, V, Jönsson, E G, Terenius, L, Agartz, I, Petursson, H, Nöthen, M M, Rietschel, M, Peltonen, L, Rujescu, D, Collier, D A, Stefansson, H, St Clair, D, and Stefansson, K

Published
2011
Full Text
View/download PDF

16. Copy number variations of chromosome 16p13.1 region associated with schizophrenia

Author

Ingason, A, Rujescu, D, Cichon, S, Sigurdsson, E, Sigmundsson, T, Pietiläinen, O P H, Buizer-Voskamp, J E, Strengman, E, Francks, C, Muglia, P, Gylfason, A, Gustafsson, O, Olason, P I, Steinberg, S, Hansen, T, Jakobsen, K D, Rasmussen, H B, Giegling, I, Möller, H-J, Hartmann, A, Crombie, C, Fraser, G, Walker, N, Lonnqvist, J, Suvisaari, J, Tuulio-Henriksson, A, Bramon, E, Kiemeney, L A, Franke, B, Murray, R, Vassos, E, Toulopoulou, T, Mühleisen, T W, Tosato, S, Ruggeri, M, Djurovic, S, Andreassen, O A, Zhang, Z, Werge, T, Ophoff, R A, Rietschel, M, Nöthen, M M, Petursson, H, Stefansson, H, Peltonen, L, Collier, D, Stefansson, K, and Clair, D M St

Published
2011
Full Text
View/download PDF

17. Adherence to the Mediterranean diet and risk of bladder cancer in the EPIC cohort study

Author

Buckland, G., Ros, M. M., Roswall, N., Bueno-de-Mesquita, H. B., Travier, N., Tjonneland, A., Kiemeney, L. A., Sacerdote, C., Tumino, R., Ljungberg, B., Gram, I. T., Weiderpass, E., Skeie, G., Malm, J., Ehrnström, R., Chang-Claude, J., Mattiello, A., Agnoli, C., Peeters, P. H., Boutron-Ruault, M. C., Fagherazzi, G., Clavel-Chapelon, F., Nilsson, L. M., Amiano, P., Trichopoulou, A., Oikonomou, E., Tsiotas, K., Sánchez, M. J., Overvad, K., Quirós, J. R., Chirlaque, M. D, Barricarte, A., Key, T. J., Allen, N. E., Khaw, K. T., Wareham, N., Riboli, E., Kaaks, R., Boeing, H., Palli, D., Romieu, I., Romaguera, D., and Gonzalez, C. A.

Published
2014
Full Text
View/download PDF

24. Genome-wide association analysis of coffee drinking suggests association with CYP1A1/CYP1A2 and NRCAM

Author

Amin, N, Byrne, E, Johnson, J, Chenevix-Trench, G, Walter, S, Nolte, I M, Vink, J M, Rawal, R, Mangino, M, Teumer, A, Keers, J C, Verwoert, G, Baumeister, S, Biffar, R, Petersmann, A, Dahmen, N, Doering, A, Isaacs, A, Broer, L, Wray, N R, Montgomery, G W, Levy, D, Psaty, B M, Gudnason, V, Chakravarti, A, Sulem, P, Gudbjartsson, D F, Kiemeney, L A, Thorsteinsdottir, U, Stefansson, K, van Rooij, F JA, Aulchenko, Y S, Hottenga, J J, Rivadeneira, F R, Hofman, A, Uitterlinden, A G, Hammond, C J, Shin, S-Y, Ikram, A, Witteman, J CM, Janssens, A CJW, Snieder, H, Tiemeier, H, Wolfenbuttel, B HR, Oostra, B A, Heath, A C, Wichmann, E, Spector, T D, Grabe, H J, Boomsma, D I, Martin, N G, and van Duijn, C M

Published
2012
Full Text
View/download PDF

26. Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study

Author

Mitra, Anita V., Bancroft, Elizabeth K., Barbachano, Yolanda, Page, Elizabeth C., Foster, C. S., Jameson, C., Mitchell, G., Lindeman, G. J., Stapleton, A., Suthers, G., Evans, D. G., Cruger, D., Blanco, I., Mercer, C., Kirk, J., Maehle, L., Hodgson, S., Walker, L., Izatt, L., Douglas, F., Tucker, K., Dorkins, H., Clowes, V., Male, A., Donaldson, A., Brewer, C., Doherty, R., Bulman, B., Osther, P. J., Salinas, M., Eccles, D., Axcrona, K., Jobson, I., Newcombe, B., Cybulski, C., Rubinstein, W. S., Buys, S., Townshend, S., Friedman, E., Domchek, S., Ramon y Cajal, T., Spigelman, A., Teo, S. H., Nicolai, N., Aaronson, N., Ardern-Jones, A., Bangma, C., Dearnaley, D., Eyfjord, J., Falconer, A., Grönberg, H., Hamdy, F., Johannsson, O., Khoo, V., Kote-Jarai, Z., Lilja, H., Lubinski, J., Melia, J., Moynihan, C., Peock, S., Rennert, G., Schröder, F., Sibley, P., Suri, M., Wilson, P., Bignon, Y. J., Strom, S., Tischkowitz, M., Liljegren, A., Ilencikova, D., Abele, A., Kyriacou, K., van Asperen, C., Kiemeney, L., Easton, D. F., and Eeles, Rosalind A.

Published
2011
Full Text
View/download PDF

45. Histopathological re-evaluations of biopsies in prostate cancer: a nationwide observational study.

Author

van Santvoort, B. W. H., van Leenders, G. J. L. H., Kiemeney, L. A., van Oort, I. M., Wieringa, S. E., Jansen, H., Vernooij, R. W. M., Hulsbergen-van de Kaa, C. A., and Aben, K. K. H.

Subjects
PROSTATE biopsy, PROSTATE cancer, PROSTATE cancer patients, SCIENTIFIC observation
Abstract

Grading prostate biopsies has an important role in determining treatment strategy. Histopathological evaluations suffer from interobserver variability and therefore biopsies may be re-evaluated. To provide insight into the extent of, characteristics associated with and clinical implications of prostate biopsy re-evaluations in daily clinical practice. Patients diagnosed with prostate cancer (PCa) by biopsy between October 2015 and April 2016 identified through the Netherlands Cancer Registry were included. The proportion of re-evaluations was assessed and characteristics were compared between patients with and without biopsy re-evaluation. Interobserver concordance of ISUP grade and EAU prognostic risk classification was determined by calculating Cohen's kappa. Biopsy re-evaluation was performed in 172 (3.3%) of 5214 patients. Primary reason for re-evaluation in patients treated with curative intent was referral to another hospital. Most referred patients treated with curative intent (n = 1856) had no re-evaluation (93.0%, n = 1727). Patients with biopsy re-evaluation were younger and underwent more often prostatectomy compared to patients without re-evaluation. The disagreement rate for ISUP grade was 26.1% and interobserver concordance was substantial (κ-weighted = 0.74). Re-evaluation resulted in 21.1% (n = 14) of patients with localised PCa in a different prognostic risk group. More tumours were downgraded (57.1%) than upgraded (42.9%). Interobserver concordance was very good (κweighted = 0.85). Pathology review of prostate biopsies is infrequently requested by clinicians in the Netherlands but in a non-negligible minority of patients with localised PCa the pathology review led to a change in prognostic risk group which might impact their treatment. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

46. Insight into bladder cancer care: study protocol of a large nationwide prospective cohort study (BlaZIB).

Author

Ripping, T. M., Kiemeney, L. A., van Hoogstraten, L. M. C., Witjes, J. A., Aben, K. K. H., on behalf of the BlaZIB study group, Boormans, Joost, de Reijke, Theo, Goossens, Catharina A., Helder, Sipke, Hulshof, Maarten C. C. M., van Leenders, Geert J. L. H., van Leliveld, Annemarie M., Meijer, Richard P., Mulder, Sasja, Nooter, Ronald I., Noteboom, Juus L., Oddens, Jorg R., Smilde, Tineke J., and Vanderbosch, Guus W. J.

Subjects
*BLADDER cancer, *LONGITUDINAL method, *COHORT analysis, *ELECTRONIC health records, *PHYSICIAN practice patterns
Abstract

Background: Despite the embedding of bladder cancer management in European guidelines, large variation in clinical practice exists for applied diagnostics and treatments. This variation may affect patients' outcomes including complications, disease recurrence, progression, survival, and health-related quality of life (HRQL). Lack of detailed clinical data and HRQL data hampers a comprehensive evaluation of bladder cancer care. Through prospective data registration, this study aims to provide insight in bladder cancer care in the Netherlands and to identify barriers and modulators of optimal bladder cancer care.Methods: This study is a nationwide prospective cohort study including all patients who were newly diagnosed with high-risk non-muscle invasive bladder cancer (HR-NMIBC; Tis and/or T1, N0, M0/x) or non-metastatic muscle invasive bladder cancer (MIBC; ≥T2, N0/x-3, M0/x) in the Netherlands between November 1st 2017 and October 31st 2019. Extensive data on patient- and tumor characteristics, diagnostics, treatment and follow-up up to 2 years after diagnosis will be collected prospectively from electronic health records in the participating hospitals by data managers of the Netherlands Cancer Registry (NCR). Additionally, patients will be requested to participate in a HRQL survey shortly after diagnosis and subsequently at 6, 12 and 24 months. The HRQL survey includes six standardized questionnaires, e.g. SCQ Comorbidity score, EQ-5D-5 L, EORTC-QLQ-C30, EORTC-QLQ-BLM30, EORTC-QLQ-NMIBC24 and BCI. Variation in care and deviation from the European guidelines will be assessed through descriptive analyses and multivariable multilevel analyses. Survival analyses will be used to assess the association between variation in care and relevant outcomes such as survival.Discussion: The results of this observational study will guide modifications of clinical practice and/or adaptation of guidelines and may set the agenda for new specific research questions in the management of bladder cancer.Trial Registration: Retrospectively registered in the Netherlands Trial Register. Trial identification number: NL8106. Registered on October 22nd 2019. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

49. Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments.

Author

De Groot, S., Blommestein, H. M., Redekop, W. K., Sleijfer, S., Kiemeney, L. A. L. M., Oosterwijk, E., and Uyl-de Groot, C. A.

Subjects
CANCER treatment, RENAL cell carcinoma, PROTEIN-tyrosine kinases, CLINICAL trials, MEDICAL care costs, COST effectiveness
Abstract

Introduction: Randomised controlled trials have shown that targeted therapies like sunitinib are effective in metastatic renal cell carcinoma (mRCC). Little is known about the current use of these therapies, and their associated costs and effects in daily clinical practice. We estimated the real-world cost-effectiveness of different treatment strategies comprising one or more sequentially administered drugs. Methods: Analyses were performed using patient-level data from a Dutch population-based registry including patients diagnosed with primary mRCC from January 2008 to December 2010 (i.e., treated between 2008 and 2013). The full disease course of these patients was estimated using a patient-level simulation model based on regression analyses of the registry data. A healthcare sector perspective was adopted; total costs included healthcare costs related to mRCC. Cost-effectiveness was expressed in cost per life-year and cost per quality-adjusted life-year (QALY) gained. Probabilistic sensitivity analysis was conducted to estimate the overall uncertainty surrounding cost-effectiveness. Results: In current daily practice, 54% (336/621) of all patients was treated with targeted therapies. Most patients (84%; 282/336) received sunitinib as first-line therapy. Of the patients receiving first-line therapy, 30% (101/336) also received second-line therapy; the majority was treated with everolimus (40%, 40/101) or sorafenib (28%, 28/101). Current treatment practice (including patients not receiving targeted therapy) led to 0.807 QALYs; mean costs were €58,912. This resulted in an additional €105,011 per QALY gained compared to not using targeted therapy at all. Forty-six percent of all patients received no targeted therapy; of these patients, 24% (69/285) was eligible for sunitinib. If these patients were treated with first-line sunitinib, mean QALYs would improve by 0.062–0.076 (where the range reflects the choice of second-line therapy). This improvement is completely driven by the health gain seen amongst patients eligible to receive sunitinib but did not receive it, who gain 0.558–0.684 QALYs from sunitinib. Since additional costs would be €7,072–9,913, incremental costs per QALY gained are €93,107–111,972 compared to current practice. Discussion: Health can be gained if more treatment-eligible patients receive targeted therapies. Moreover, it will be just as cost-effective to treat these patients with sunitinib as current treatment practice. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

50. Variation in use of targeted therapies for metastatic renal cell carcinoma: Results from a Dutch population-based registry.

Author

De Groot, S., Sleijfer, S., Redekop, W. K., Oosterwijk, E., Haanen, J. B. A. G., Kiemeney, L. A. L. M., and Uyl-de Groot, C. A.

Subjects
RENAL cell carcinoma, LOGISTIC regression analysis, METASTASIS, SURVIVAL, CANCER, ANTINEOPLASTIC agents, HETEROCYCLIC compounds, INDOLE compounds, SULFONAMIDES, DRUG therapy, KIDNEY tumors, MEDICAL prescriptions, SURVIVAL analysis (Biometry), TREATMENT effectiveness, ACQUISITION of data, RETROSPECTIVE studies, THERAPEUTICS
Abstract

Background: For patients with metastatic renal cell carcinoma (mRCC), targeted therapies have entered the market since 2006. The aims of this study were to evaluate the uptake and use of targeted therapies for mRCC in The Netherlands, examine factors associated with the prescription of targeted therapies in daily clinical practice and study their effectiveness in terms of overall survival (OS).Methods: Two cohorts from PERCEPTION, a population-based registry of mRCC patients, were used: a 2008-2010 Cohort (n = 645) and a 2011-2013 Cohort (n = 233). Chi-squared tests for trend were used to study time trends in the use of targeted therapy. Patients were grouped based on the eligibility criteria of the SUTENT trial, the trial that led to sunitinib becoming standard of care, to investigate the use of targeted therapies amongst patients fulfilling those criteria. Multi-level logistic regression was used to identify patient subgroups that are less likely to receive targeted therapies.Results: Approximately one-third of patients fulfilling SUTENT trial eligibility criteria did not receive any targeted therapy (29 % in the 2008-2010 Cohort; 35 % in the 2011-2013 Cohort). Patients aged 65+ years were less likely to receive targeted therapy in both cohorts and different risk groups (odds ratios range between 0.84-0.92); other factors like number of metastatic sites were of influence in some subgroups. Amongst treated patients, there was a decreasing trend in sunitinib use over time (p = 0.0061), and an increasing trend in pazopanib use (p = 0.0005).Conclusions: Targeted therapies have largely replaced interferon-alfa as first-line standard of care. Nevertheless, many eligible patients in Dutch daily practice did not receive targeted therapies despite their ability to improve survival. Reasons for their apparent underutilisation should be examined more carefully. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results